CryoPort Partners with Verismo to Enhance KIR-CAR Program Development with Cryopreservation Services

CryoPort, Inc. (CYRX) strengthens its position in the life sciences sector through its recent collaboration with Verismo Therapeutics. The partnership focuses on CryoPort’s IntegriCell® cryopreservation services, which are critical for supporting the development of Verismo's novel KIR-CAR programs, including SynKIR™-110 and SynKIR™-310. These lead candidates are currently undergoing human clinical trials, with significant data presented at the 2026 AACR Annual Meeting. By utilizing CryoPort's GMP-compliant cryopreservation techniques, Verismo aims to enhance manufacturing efficiency, mitigate supply chain risks, and reduce variability in its pivotal operations, essential for the maturation of their therapeutic programs.

CryoPort's Role in Advancing Innovative Therapies

In achieving these objectives, CryoPort plays a transformative role. Dr. Mark Sawicki, CEO of Cryoport Systems, comments on the importance of partnering with developers to refine and scale critical processes as their programs mature. This strategic alliance underscores how vital integrated temperature-controlled supply chains are for life sciences, particularly in an era where innovative therapies are developed rapidly. Verismo's KIR-CAR candidates are at the forefront of targeted therapies, with SynKIR™-110 being evaluated in the STAR-101 trial for advanced mesothelin-expressing solid tumors and SynKIR™-310 in the CELESTIAL-301 trial for relapsed or refractory B-cell non-Hodgkin lymphomas.

Strategic Collaboration for Regulatory Milestones

Bryan Kim, CEO and Co-Founder of Verismo Therapeutics, emphasizes that the implementation of IntegriCell’s cryopreservation process ensures improved workflow cohesion and enhances process control and scalability. This collaboration marks a significant step forward in achieving the clinical and regulatory milestones required for the advancement of Verismo's innovative KIR-CAR platform, indicative of how essential advanced cryopreservation services have become in the evolution of cell and gene therapies.

Conclusion

Overall, CryoPort's ongoing commitment to facilitating innovative therapeutic advancements highlights the importance of its cryopreservation services in the competitive landscape of life sciences. As the demand for efficient and reliable temperature-controlled supply chains continues to grow, partnerships like the one with Verismo pave the way for cutting-edge developments that could redefine treatment options for patients globally.